SlideShare uma empresa Scribd logo
Blood based biomarkers
Why do we want them? Exactly what do we want? How will we get it ?
Adapted from Sperling et al (2011) Alzheimer’s and dementia 7 280-92
Why do we want (blood based) biomarkers ?
-
1.0
0.6
0.2
1.4
1.8
Relativeopticaldensity
P<0.05
0.0 0.2 0.4 0.6 0.8 1.0
1 - Specificity
0.0
0.2
0.4
0.6
0.8
1.0
Sensitivity
ROC Curve
Complement Factor H (CFH)
n>500
Proof of a signal in blood
(also complement c4 – decreased)
Biomarkers for prediction
‘Conversion’, progression and sub-type
Companion biomarkers
Specific to target/therapy
Biomarkers for pathology
Discovery by endophenotype
Biomarkers for clinical trials
Stratification and experimental medicine
What, exactly, do we want ?
Biomarkers for AD
not needed, not possible
Correlation with cortical atrophy
Correlation with cognition (MMSE)
Correlation with speed of decline
Design matters
In man….
W/T APP/PS1
In mouse….
European Medical Information Framework
Vision: To enable and conduct novel research
into human health by utilising human health data
at an unprecedented scale
• Access to information on 40 million patients
• Cohorts with samples, imaging and clinical data :
• > 20,000 for dementia and metabolic biomarker discovery and validation
• Linkage of clinical and omics data
• Development of a secure (privacy, legal) modular platform
• Continue to build a network of data sources and relevant research
http://www.imi.europa.eu/content/emif
How will we get biomarkers ?
EMIF – a public private partnership for data-integration
EMIF-Metabolic
EMIF-AD
Data Privacy
Analytical tools
Semantic Integration
Information standards
Data access / mgmt
IMI Structure and Network
Research Topics
EMIF governance
Preventionalgorithms
Predictivescreening
Riskstratification
Call 5Call 5
Riskfactoranalysis
Patientgenerateddata
TBD
EMIF-Platform
Metabolic CNS
Maudsley BRC
Informatics team
Martina Sattlecker
Steven Kiddle
Steve Newhouse
Anbarasu Lourdasamy
Simon Furney
Gerome Breen
Rob Stewart
Mike Denis
Richard Dobson
King’s College London
Biomarkers team
Abdul Hye
Joanna Riddoch-Contreras
Rufina Leung
Andreas Guentert
Mohammed Aiyaz
Madhav Thambisetty (NIA)
Katie Lunnon
Alison Baird
Nicholas Ashton
Sarah Westwood
Latha Velayudhan
Chantal Bazenet
Angela Hodges
Simon Lovestone
AddNeuroMed
Imaging team
Eric Westman
Sebastian Muehlboeck
Sergi Costafreda
Lars-Olof Wahlund
Christian Spenger
Alan Evans
Andrew Simmons
AddNeuroMed
Clinical team
Hilkka Soininen
Bruno Vellas
Patrizia Meccocci
Magda Tsolaki
Iwona Kłoszewska
Simon Lovestone

Mais conteúdo relacionado

Semelhante a Alz forum lovestone (short)

Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
New York City College of Technology Computer Systems Technology Colloquium
 
Haendel clingenetics.3.14.14
Haendel clingenetics.3.14.14Haendel clingenetics.3.14.14
Haendel clingenetics.3.14.14
mhaendel
 
Integrative and translational analysis of the phenome
Integrative and translational analysis of the phenomeIntegrative and translational analysis of the phenome
Integrative and translational analysis of the phenome
Robert Hoehndorf
 
PibPET_iTRAQ_JAD2016
PibPET_iTRAQ_JAD2016PibPET_iTRAQ_JAD2016
PibPET_iTRAQ_JAD2016
Je-Hyun Baek
 
C3 Neurological Complications and Treatment of HIV Clifford
C3 Neurological Complications and Treatment of HIV CliffordC3 Neurological Complications and Treatment of HIV Clifford
C3 Neurological Complications and Treatment of HIV Clifford
DSHS
 
Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...
Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
Alia Iqniebi
 

Semelhante a Alz forum lovestone (short) (20)

The Application of the Human Phenotype Ontology
The Application of the Human Phenotype Ontology The Application of the Human Phenotype Ontology
The Application of the Human Phenotype Ontology
 
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
Pharmacology Powered by Computational Analysis: Predicting Cardiotoxicity of ...
 
GA4GH Phenotype Ontologies Task team update
GA4GH Phenotype Ontologies Task team updateGA4GH Phenotype Ontologies Task team update
GA4GH Phenotype Ontologies Task team update
 
Parkinson's 2015 meeting 2nd July London
Parkinson's 2015 meeting 2nd July LondonParkinson's 2015 meeting 2nd July London
Parkinson's 2015 meeting 2nd July London
 
Haendel clingenetics.3.14.14
Haendel clingenetics.3.14.14Haendel clingenetics.3.14.14
Haendel clingenetics.3.14.14
 
La struttura della medicina di precisione
La struttura della medicina di precisioneLa struttura della medicina di precisione
La struttura della medicina di precisione
 
임상의사 관점의 의료빅데이터 연구와 임상적용 - From Clinic To Data, From Data To Clinic
임상의사 관점의 의료빅데이터 연구와 임상적용 - From Clinic To Data, From Data To Clinic임상의사 관점의 의료빅데이터 연구와 임상적용 - From Clinic To Data, From Data To Clinic
임상의사 관점의 의료빅데이터 연구와 임상적용 - From Clinic To Data, From Data To Clinic
 
Medical Statistics Pt 1
Medical Statistics Pt 1Medical Statistics Pt 1
Medical Statistics Pt 1
 
Integrative and translational analysis of the phenome
Integrative and translational analysis of the phenomeIntegrative and translational analysis of the phenome
Integrative and translational analysis of the phenome
 
PibPET_iTRAQ_JAD2016
PibPET_iTRAQ_JAD2016PibPET_iTRAQ_JAD2016
PibPET_iTRAQ_JAD2016
 
Biomarker Diagnosis for Alzheimer's Disease
Biomarker Diagnosis for Alzheimer's DiseaseBiomarker Diagnosis for Alzheimer's Disease
Biomarker Diagnosis for Alzheimer's Disease
 
tranSMART Community Meeting 5-7 Nov 13 - Session 2: Creating a Comprehensive ...
tranSMART Community Meeting 5-7 Nov 13 - Session 2: Creating a Comprehensive ...tranSMART Community Meeting 5-7 Nov 13 - Session 2: Creating a Comprehensive ...
tranSMART Community Meeting 5-7 Nov 13 - Session 2: Creating a Comprehensive ...
 
Tulane Workshop on Multi-omics integration
Tulane Workshop on Multi-omics integrationTulane Workshop on Multi-omics integration
Tulane Workshop on Multi-omics integration
 
C3 Neurological Complications and Treatment of HIV Clifford
C3 Neurological Complications and Treatment of HIV CliffordC3 Neurological Complications and Treatment of HIV Clifford
C3 Neurological Complications and Treatment of HIV Clifford
 
Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...Association Study of Single  Nucleotide Polymorphism of PTH  Gene in Osteopor...
Association Study of Single Nucleotide Polymorphism of PTH Gene in Osteopor...
 
Biomarkers in Ambulatory HF: What to Test and How Often?
Biomarkers in Ambulatory HF: What to Test and How Often?Biomarkers in Ambulatory HF: What to Test and How Often?
Biomarkers in Ambulatory HF: What to Test and How Often?
 
헬스케어 빅데이터로 무엇을 할 수 있는가?
헬스케어 빅데이터로 무엇을 할 수 있는가?헬스케어 빅데이터로 무엇을 할 수 있는가?
헬스케어 빅데이터로 무엇을 할 수 있는가?
 
Clinical phentypes of sepsis
Clinical phentypes of sepsisClinical phentypes of sepsis
Clinical phentypes of sepsis
 
Troponin use it in all patients with acute heart failure contra
Troponin use it in all patients with acute heart failure contraTroponin use it in all patients with acute heart failure contra
Troponin use it in all patients with acute heart failure contra
 
Heart Failure biomarkers
Heart Failure biomarkersHeart Failure biomarkers
Heart Failure biomarkers
 

Mais de Alzforum

Mais de Alzforum (20)

First Identification of Role TMEM106B in FTD
First Identification of Role TMEM106B in FTDFirst Identification of Role TMEM106B in FTD
First Identification of Role TMEM106B in FTD
 
Protein-RNA Complexes, ALS and Aging
Protein-RNA Complexes, ALS and AgingProtein-RNA Complexes, ALS and Aging
Protein-RNA Complexes, ALS and Aging
 
Lifespan vs. Healthspan
Lifespan vs. HealthspanLifespan vs. Healthspan
Lifespan vs. Healthspan
 
Genetic regulation of human brain aging
Genetic regulation of human brain agingGenetic regulation of human brain aging
Genetic regulation of human brain aging
 
Marc Dhenain Alzforum Webinar - Dec 7, 2016
Marc Dhenain Alzforum Webinar - Dec 7, 2016Marc Dhenain Alzforum Webinar - Dec 7, 2016
Marc Dhenain Alzforum Webinar - Dec 7, 2016
 
Peter Nelson Alzforum Webinar - Dec 7, 2016
Peter Nelson Alzforum Webinar - Dec 7, 2016Peter Nelson Alzforum Webinar - Dec 7, 2016
Peter Nelson Alzforum Webinar - Dec 7, 2016
 
Elizabeth Head Alzforum Webinar - Dec 7, 2016
Elizabeth Head Alzforum Webinar - Dec 7, 2016Elizabeth Head Alzforum Webinar - Dec 7, 2016
Elizabeth Head Alzforum Webinar - Dec 7, 2016
 
Patrick Hof Alzforum Webinar - Dec 7, 2016
Patrick Hof Alzforum Webinar - Dec 7, 2016Patrick Hof Alzforum Webinar - Dec 7, 2016
Patrick Hof Alzforum Webinar - Dec 7, 2016
 
Lary Walker Introduction Webinar
Lary Walker Introduction WebinarLary Walker Introduction Webinar
Lary Walker Introduction Webinar
 
Henrik Zetterberg - Alzforum webinar April 29, 2016
Henrik Zetterberg - Alzforum webinar April 29, 2016Henrik Zetterberg - Alzforum webinar April 29, 2016
Henrik Zetterberg - Alzforum webinar April 29, 2016
 
Johannes Streffer - Alzforum webinar April 29, 2016
Johannes Streffer - Alzforum webinar April 29, 2016Johannes Streffer - Alzforum webinar April 29, 2016
Johannes Streffer - Alzforum webinar April 29, 2016
 
Byron Caughey
Byron CaugheyByron Caughey
Byron Caughey
 
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
Dominic Walsh - A Critical Appraisal of the Pathogenic Protein Spread Hypothe...
 
David Harris -
David Harris - David Harris -
David Harris -
 
Patrik Brundin - Are Synucleinopathies Prion Diseases?
Patrik Brundin - Are Synucleinopathies Prion Diseases?Patrik Brundin - Are Synucleinopathies Prion Diseases?
Patrik Brundin - Are Synucleinopathies Prion Diseases?
 
Virginia Lee - Cell-to-Cell Spread of Pathological Tau
Virginia Lee - Cell-to-Cell Spread of Pathological TauVirginia Lee - Cell-to-Cell Spread of Pathological Tau
Virginia Lee - Cell-to-Cell Spread of Pathological Tau
 
The cellular phase of Alzheimer's disease
The cellular phase of Alzheimer's diseaseThe cellular phase of Alzheimer's disease
The cellular phase of Alzheimer's disease
 
Hendrix 2015 composite endpoints redacted
Hendrix 2015 composite endpoints redacted Hendrix 2015 composite endpoints redacted
Hendrix 2015 composite endpoints redacted
 
Cliff Brangwynne
Cliff BrangwynneCliff Brangwynne
Cliff Brangwynne
 
Paul Taylor
Paul Taylor Paul Taylor
Paul Taylor
 

Último

Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Peter Udo Diehl
 

Último (20)

Buy Epson EcoTank L3210 Colour Printer Online.pdf
Buy Epson EcoTank L3210 Colour Printer Online.pdfBuy Epson EcoTank L3210 Colour Printer Online.pdf
Buy Epson EcoTank L3210 Colour Printer Online.pdf
 
IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024IoT Analytics Company Presentation May 2024
IoT Analytics Company Presentation May 2024
 
Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024Enterprise Knowledge Graphs - Data Summit 2024
Enterprise Knowledge Graphs - Data Summit 2024
 
ECS 2024 Teams Premium - Pretty Secure
ECS 2024   Teams Premium - Pretty SecureECS 2024   Teams Premium - Pretty Secure
ECS 2024 Teams Premium - Pretty Secure
 
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
ASRock Industrial FDO Solutions in Action for Industrial Edge AI _ Kenny at A...
 
Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024Extensible Python: Robustness through Addition - PyCon 2024
Extensible Python: Robustness through Addition - PyCon 2024
 
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
Choosing the Right FDO Deployment Model for Your Application _ Geoffrey at In...
 
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo DiehlFuture Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
Future Visions: Predictions to Guide and Time Tech Innovation, Peter Udo Diehl
 
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdfThe Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
The Value of Certifying Products for FDO _ Paul at FIDO Alliance.pdf
 
10 Differences between Sales Cloud and CPQ, Blanka Doktorová
10 Differences between Sales Cloud and CPQ, Blanka Doktorová10 Differences between Sales Cloud and CPQ, Blanka Doktorová
10 Differences between Sales Cloud and CPQ, Blanka Doktorová
 
Designing for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at ComcastDesigning for Hardware Accessibility at Comcast
Designing for Hardware Accessibility at Comcast
 
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptxUnpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
Unpacking Value Delivery - Agile Oxford Meetup - May 2024.pptx
 
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi IbrahimzadeFree and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
Free and Effective: Making Flows Publicly Accessible, Yumi Ibrahimzade
 
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya HalderCustom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
Custom Approval Process: A New Perspective, Pavel Hrbacek & Anindya Halder
 
Syngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdfSyngulon - Selection technology May 2024.pdf
Syngulon - Selection technology May 2024.pdf
 
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptxWSO2CONMay2024OpenSourceConferenceDebrief.pptx
WSO2CONMay2024OpenSourceConferenceDebrief.pptx
 
IESVE for Early Stage Design and Planning
IESVE for Early Stage Design and PlanningIESVE for Early Stage Design and Planning
IESVE for Early Stage Design and Planning
 
Buy Epson EcoTank L3210 Colour Printer Online.pptx
Buy Epson EcoTank L3210 Colour Printer Online.pptxBuy Epson EcoTank L3210 Colour Printer Online.pptx
Buy Epson EcoTank L3210 Colour Printer Online.pptx
 
Agentic RAG What it is its types applications and implementation.pdf
Agentic RAG What it is its types applications and implementation.pdfAgentic RAG What it is its types applications and implementation.pdf
Agentic RAG What it is its types applications and implementation.pdf
 
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdfIntroduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
Introduction to FDO and How It works Applications _ Richard at FIDO Alliance.pdf
 

Alz forum lovestone (short)

  • 1. Blood based biomarkers Why do we want them? Exactly what do we want? How will we get it ?
  • 2. Adapted from Sperling et al (2011) Alzheimer’s and dementia 7 280-92 Why do we want (blood based) biomarkers ?
  • 3. - 1.0 0.6 0.2 1.4 1.8 Relativeopticaldensity P<0.05 0.0 0.2 0.4 0.6 0.8 1.0 1 - Specificity 0.0 0.2 0.4 0.6 0.8 1.0 Sensitivity ROC Curve Complement Factor H (CFH) n>500 Proof of a signal in blood (also complement c4 – decreased)
  • 4. Biomarkers for prediction ‘Conversion’, progression and sub-type Companion biomarkers Specific to target/therapy Biomarkers for pathology Discovery by endophenotype Biomarkers for clinical trials Stratification and experimental medicine What, exactly, do we want ? Biomarkers for AD not needed, not possible
  • 5. Correlation with cortical atrophy Correlation with cognition (MMSE) Correlation with speed of decline Design matters In man…. W/T APP/PS1 In mouse….
  • 6. European Medical Information Framework Vision: To enable and conduct novel research into human health by utilising human health data at an unprecedented scale • Access to information on 40 million patients • Cohorts with samples, imaging and clinical data : • > 20,000 for dementia and metabolic biomarker discovery and validation • Linkage of clinical and omics data • Development of a secure (privacy, legal) modular platform • Continue to build a network of data sources and relevant research http://www.imi.europa.eu/content/emif How will we get biomarkers ?
  • 7. EMIF – a public private partnership for data-integration EMIF-Metabolic EMIF-AD Data Privacy Analytical tools Semantic Integration Information standards Data access / mgmt IMI Structure and Network Research Topics EMIF governance Preventionalgorithms Predictivescreening Riskstratification Call 5Call 5 Riskfactoranalysis Patientgenerateddata TBD EMIF-Platform Metabolic CNS
  • 8. Maudsley BRC Informatics team Martina Sattlecker Steven Kiddle Steve Newhouse Anbarasu Lourdasamy Simon Furney Gerome Breen Rob Stewart Mike Denis Richard Dobson King’s College London Biomarkers team Abdul Hye Joanna Riddoch-Contreras Rufina Leung Andreas Guentert Mohammed Aiyaz Madhav Thambisetty (NIA) Katie Lunnon Alison Baird Nicholas Ashton Sarah Westwood Latha Velayudhan Chantal Bazenet Angela Hodges Simon Lovestone AddNeuroMed Imaging team Eric Westman Sebastian Muehlboeck Sergi Costafreda Lars-Olof Wahlund Christian Spenger Alan Evans Andrew Simmons AddNeuroMed Clinical team Hilkka Soininen Bruno Vellas Patrizia Meccocci Magda Tsolaki Iwona Kłoszewska Simon Lovestone